- AstraZeneca's Zegfrovy approved in US and China for adults with EGFR exon20 insertion NSCLC after platinum chemo; granted Breakthrough Therapy for first-line use and listed in NCCN guidelines.
- Berenberg cut AstraZeneca (AZN) PT to £160 from £170, kept Buy; cited Wainua setback and lower R&D premium. Stock fell about 1.3% to £126.68 after the update.
TradingView
Key facts: Zegfrovy OK in US/China for EGFR exon20 NSCLC; AZN PT £160
- Sources
- TradingView
- Active symbols
- LSE:AZN
- Language
- English (India)
AstraZeneca's Zegfrovy approved in US and China for adults with EGFR exon20 insertion NSCLC after platinum chemo; granted Breakthrough Therapy for first-line use and listed in NCCN